5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital

2. Novavax, Inc. (NASDAQ:NVAX)

RA Capital Management’s Stake Value: $434 million

Percentage of RA Capital Management’s 13F Portfolio: 6.02%

Number of Hedge Fund Holders: 35

Novavax, Inc. (NASDAQ:NVAX) is a vaccine developer that is targeting diseases such as Covid-19, influenza, Ebola, and other respiratory viruses. It was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Dr. Kolchinsky’s RA Capital held 2 million Novavax, Inc. (NASDAQ:NVAX) shares in the third quarter of this year. These were worth $434 million and represented 6.02% of the firm’s investment portfolio.

Novavax, Inc. (NASDAQ:NVAX) earned $178 million in revenue and -$4.31 in GAAP EPS during its third quarter. At a September conference, the company outlined that it plans to double its COVID-19 vaccine manufacturing capacity to ship 2 billion doses next year. B. Riley kept the company’s price target at $305 in a November 2021 analyst note, highlighting that more regulatory approvals were headed their way this year.